{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:48:28Z","timestamp":1789674508023,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12974-015-0365-x","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T19:29:56Z","timestamp":1439234996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-8879","authenticated-orcid":false,"given":"Michela","family":"Spadaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Caldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Marnetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,12]]},"reference":[{"key":"365_CR1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","volume":"4","author":"RA Rudick","year":"2004","unstructured":"Rudick RA, Sandrock A. Natalizumab: \u03b14-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4:571\u201380.","journal-title":"Expert Rev Neurother"},{"key":"365_CR2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrd1752","volume":"4","author":"L Steinman","year":"2005","unstructured":"Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discovery. 2005;4:510\u20138.","journal-title":"Nat Rev Drug Discovery"},{"issue":"9","key":"365_CR3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"365_CR4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000360528","volume":"72","author":"CP Kamm","year":"2014","unstructured":"Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol. 2014;72(3\u20134):132\u201341.","journal-title":"Eur Neurol"},{"issue":"10","key":"365_CR5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/imj.12558","volume":"44","author":"L Sedal","year":"2014","unstructured":"Sedal L, Wilson IB, McDonald EA. Current management of relapsing-remitting multiple sclerosis. Intern Med J. 2014;44(10):950\u20137.","journal-title":"Intern Med J"},{"issue":"4","key":"365_CR6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archopht.1977.04450040122019","volume":"95","author":"RE Appen","year":"1977","unstructured":"Appen RE, Roth H, ZuRhein GM, Varakis JN. Progressive multifocal leukoencephalopathy. A cause of visual loss. Arch Ophthalmol. 1977;95(4):656\u20139.","journal-title":"Arch Ophthalmol"},{"key":"365_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","volume":"61","author":"EO Major","year":"2010","unstructured":"Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35\u201347.","journal-title":"Annu Rev Med"},{"issue":"2","key":"365_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS S\u00f8rensen","year":"2012","unstructured":"S\u00f8rensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler J. 2012;18(2):143\u201352.","journal-title":"Mult Scler J"},{"issue":"6","key":"365_CR9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802\u201312.","journal-title":"Ann Neurol"},{"issue":"10","key":"365_CR10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","volume":"81","author":"N Schwab","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, G\u00f6bel K, Windhagen S, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81(10):865\u201371.","journal-title":"Neurology"},{"key":"365_CR11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69:292\u2013302.","journal-title":"Ann Neurol"},{"issue":"6","key":"365_CR12","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.2353\/ajpath.2010.100442","volume":"177","author":"AM Herrmann","year":"2010","unstructured":"Herrmann AM, G\u00f6bel K, Simon OJ, Melzer N, Schuhmann MK, Stenner MP, et al. Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. Am J Pathol. 2010;177(6):3051\u201360.","journal-title":"Am J Pathol"},{"issue":"3","key":"365_CR13","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/ndt\/gfg599","volume":"19","author":"T B\u00f6hler","year":"2004","unstructured":"B\u00f6hler T, Waiser J, Schuetz M, Neumayer HH, Budde K. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant. 2004;19(3):702\u201313.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"365_CR14","doi-asserted-by":"crossref","first-page":"e47578","DOI":"10.1371\/journal.pone.0047578","volume":"7","author":"L B\u00f6rnsen","year":"2012","unstructured":"B\u00f6rnsen L, Christensen JR, Ratzer R, Oturai AB, S\u00f8rensen PS, et al. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis. PLoS ONE. 2012;7(11):e47578.","journal-title":"PLoS ONE"},{"issue":"7","key":"365_CR15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103716","volume":"9","author":"P Kivis\u00e4kk","year":"2014","unstructured":"Kivis\u00e4kk P, Francois K, Mbianda J, Gandhi R, Weiner HL, Khoury SJ. Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis. PLoS ONE. 2014;9(7), e103716.","journal-title":"PLoS ONE"},{"issue":"2","key":"365_CR16","first-page":"151","volume":"33","author":"M Feuerecker","year":"2012","unstructured":"Feuerecker M, Kaufmann I, Salam AP, Chouk\u00e8r A. Effects of cryopreservation with polyethylene glycol on the expression of CD11b and CD62L on the surface of polymorphonuclear leukocytes. Cryo Letters. 2012;33(2):151\u201360.","journal-title":"Cryo Letters"},{"key":"365_CR17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000302687","volume":"63","author":"N Putzki","year":"2010","unstructured":"Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol. 2010;63:311\u20137.","journal-title":"Eur Neurol"},{"key":"365_CR18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/1352458510392263","volume":"17","author":"G Frisullo","year":"2011","unstructured":"Frisullo G, Iorio R, Plantone D, Marti A, Nociti V, Patanella AK, et al. CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler. 2011;17:556\u201366.","journal-title":"Mult Scler"},{"issue":"20","key":"365_CR19","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870\u201380.","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-015-0365-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T13:21:42Z","timestamp":1498224102000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jneuroinflammation.com\/content\/12\/1\/146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["365"],"URL":"https:\/\/doi.org\/10.1186\/s12974-015-0365-x","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,12]]},"article-number":"146"}}